Inovio Pharmaceuticals Inc. (INO)’s Financial Results Comparing With Evofem Biosciences Inc. (NASDAQ:EVFM)

Since Inovio Pharmaceuticals Inc. (NASDAQ:INO) and Evofem Biosciences Inc. (NASDAQ:EVFM) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inovio Pharmaceuticals Inc. 36.77M 11.81 85.51M -0.94 0.00
Evofem Biosciences Inc. N/A 0.00 131.47M -7.47 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Inovio Pharmaceuticals Inc. and Evofem Biosciences Inc.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals Inc. -232.55% -72.7% -52.6%
Evofem Biosciences Inc. 0.00% 144.8% -836%

Risk & Volatility

Inovio Pharmaceuticals Inc.’s 1.67 beta indicates that its volatility is 67.00% more volatile than that of S&P 500. Evofem Biosciences Inc.’s 179.00% more volatile than S&P 500 which is a result of the 2.79 beta.


The Current Ratio of Inovio Pharmaceuticals Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival Evofem Biosciences Inc. is 0.5 and its Quick Ratio is has 0.5. Inovio Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Evofem Biosciences Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Inovio Pharmaceuticals Inc. and Evofem Biosciences Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Inovio Pharmaceuticals Inc. 0 0 2 3.00
Evofem Biosciences Inc. 0 0 0 0.00

The consensus target price of Inovio Pharmaceuticals Inc. is $10.5, with potential upside of 130.53%.

Institutional & Insider Ownership

Institutional investors owned 35% of Inovio Pharmaceuticals Inc. shares and 79.8% of Evofem Biosciences Inc. shares. Inovio Pharmaceuticals Inc.’s share owned by insiders are 2.5%. On the other hand, insiders owned about 3% of Evofem Biosciences Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Inovio Pharmaceuticals Inc. -2.99% -0.76% -4.77% 15.85% 18.49% 25.67%
Evofem Biosciences Inc. 10% 8.15% -5.41% 2.67% -50.64% -67.09%

For the past year Inovio Pharmaceuticals Inc. had bullish trend while Evofem Biosciences Inc. had bearish trend.


Inovio Pharmaceuticals Inc. beats on 8 of the 10 factors Evofem Biosciences Inc.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companyÂ’s partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.